Phase 2 N=33 Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Adverse Drug Reactions — 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Overall Survival — 37 participants
Phase 2 N=72 The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients
Dry Eye
Primary: Change From Baseline on the National Eye Institute Corneal Staining Scale (NEI-CSS) at Week 4 — 0.23; 0.12; 0.26 Units on a scale
Phase 2 N=60 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Abdominal Obesity · Growth Hormone Deficiency
Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2
Phase 2 N=6 Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
Arthritis, Gouty
Primary: Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale — 100; 100 Percentage of participants
Phase 2 N=39 Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma With Sarcomatoid Features
Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants
Phase 2 N=72 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Lung Cancer
Primary: Objective Response Rate (Proportion of Patients With Objective Response) — 0.07 Proportion
Phase 2 N=12 A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
Hereditary Angioedema
Primary: Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw…
Phase 2 N=37 Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Lung Cancer
Primary: Response by RECIST Criteria (v 1.0) — 3; 5; 11; 15 participants
Phase 2 N=175 Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Melanoma (Skin)
Primary: Cytotoxic T-cell Lymphocytes (CTL) Response Rate — 43; 47; 28; 5 percentage of participants — p=<0.001
Phase 2 N=38 Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary: Percentage of Participants With Objective Response (OR) — 39.5 Percentage of participants
Phase 2 N=386 A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 31.48; 45.10; 61.22; 72.13 percentage of participants
Phase 2 N=40 Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
Hypogonadism
Primary: Percent of Subjects With Testosterone Levels in the Normal Range. — 68.4 percentage of participants
Phase 2 N=13 Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
Hyperoxaluria
Primary: Urinary Oxalate Excretion — 1.43; 1.04 umol/mg — p=0.007
Phase 2 N=31 The Effects of Thalidomide on Symptom Clusters
Advanced Cancers
Primary: Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS) — 3; 3; 4; 3 units on a scale